AbCellera Biologics Inc. (ABCL)
↓ Download CSV- Sector Manufacturing
- Incorporated A1
- Fiscal year ends Dec 31
In fiscal 2025, AbCellera Biologics Inc. reported revenue of $75.13M, up 160.6% from the prior year. The company ran a net loss, with a net margin of -194.9%. It held $1.36B in total assets against $390.05M in total liabilities.
Key ratios (FY2025)
-289.0%
Operating margin
-194.9%
Net margin
-15.1%
Return on equity
+160.6%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $75.13M | $28.83M | $38.02M | $485.42M | $375.20M | $233.16M | $11.61M | — |
| Operating Income | -$217.10M | -$314.77M | -$237.21M | $216.51M | $204.41M | $156.03M | -$4.12M | — |
| Net Income | -$146.41M | -$162.86M | -$146.40M | $158.52M | $153.46M | $118.92M | -$2.21M | — |
| EPS (Diluted) | $-0.49 | $-0.55 | $-0.51 | $0.50 | $0.48 | $0.45 | $-0.01 | — |
| Total Assets | $1.36B | $1.36B | $1.49B | $1.54B | $1.32B | $1.01B | — | — |
| Total Liabilities | $390.05M | $304.47M | $335.78M | $307.63M | $292.84M | $175.03M | — | — |
| Shareholders' Equity | $966.90M | $1.06B | $1.15B | $1.23B | $1.03B | $830.51M | $10.25M | $11.61M |
| Cash & Equivalents | $128.51M | $156.32M | $133.32M | $386.54M | $476.14M | $594.12M | — | — |
| Operating Cash Flow | -$131.29M | -$108.56M | -$43.88M | $277.36M | $244.58M | $22.69M | $2.69M | — |
| Capital Expenditures | $42.77M | $78.40M | $76.95M | $70.66M | $58.45M | $9.67M | $4.00M | — |
| Shares Outstanding | 298.71M | 294.33M | 289.17M | 314.83M | 318.29M | 263.13M | 151.33M | — |